Market revenue in 2023 | USD 279.8 million |
Market revenue in 2030 | USD 309.7 million |
Growth rate | 1.5% (CAGR from 2023 to 2030) |
Largest segment | Immunoturbidimetric assay |
Fastest growing segment | Immunoturbidimetric Assay |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunoturbidimetric Assay, Chemiluminescence Immunoassay, Other Assay Types, ELISA |
Key market players worldwide | Thermo Fisher Scientific Inc, Roche Holding AG ADR, Danaher Corp, Quest Diagnostics Inc, Siemens Healthineers AG ADR, Abbott Laboratories, Merck KGaA, Zoetis Inc Class A, QuidelOrtho Corp, Horiba Ltd, Getein Biotech, Boditech Med, Randox, Aidian |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to c-reactive protein testing market will help companies and investors design strategic landscapes.
Immunoturbidimetric assay was the largest segment with a revenue share of 48.5% in 2023. Horizon Databook has segmented the China c-reactive protein testing market based on immunoturbidimetric assay, chemiluminescence immunoassay, other assay types, elisa covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the most populous countries in the world and provides a large customer base to manufacturers operating in the CRP testing market. Moreover, continuously evolving healthcare infrastructure has attracted several players from the west to invest in Chinese CRP testing market.
In addition, continuous R&D in the field of inflammation testing has led to evolution of novel systems that are quick and efficient. For instance, researchers at the University of Hong Kong (HKU) have developed an advanced, ultra-thin sensor for inflammation testing using CRP, which accelerated the testing and curing time by 30-folds.
This is expected to boost adoption of CRP tests by hospitals and clinics in China. In addition, investigations by several governments, nongovernment, and academic institutions to assess and improve the effectiveness of CRP tests is expected to propel the market growth throughout the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the China c-reactive protein testing market , including forecasts for subscribers. This country databook contains high-level insights into China c-reactive protein testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account